GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70698 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jirawan Vienghirun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Mahasarakham University.
Abstract (Originalsprache)
Aim
This study used a network meta‐analysis (NMA) as the primary approach to compare the efficacy and tolerability of GLP‐1 receptor agonists and dual agonists in overweight or obese adults with and without Type 2 diabetes. Materials and Methods PubMed, Embase, Scopus, CENTRAL, and trial registries were searched through April 30, 2025. Randomized clinical trials (RCTs) of GLP‐1 receptor agonists in adults with and without Type 2 diabetes were included. Data were extracted according to PRISMA 2020. Pairwise and using random‐effects models were performed, with treatment rankings derived using SUCRA. Outcomes included ≥ 5% and ≥ 10% weight loss, weight change (absolute and percentage weight loss) at 24–52 weeks, and adverse events.
Results
A total of 127 RCTs (58 976) Participants; (39 520 with and 19 456 without T2DM) assessed seven GLP‐1RAs. Compared to placebo, NMA indicated that tirzepatide, subcutaneous semaglutide (Semaglutide_SC), and oral semaglutide (Semaglutide_oral) increased ≥ 5% weight loss (RR 7.17 [95% CI 4.38–11.73], 4.74 [3.17–7.08], 2.85 [1.78–4.58]) in T2DM. Only tirzepatide and Semaglutide_SC were effective (2.99 [1.20–7.44], 2.75 [1.14–6.61]) in non‐T2DM. For ≥ 10% loss, tirzepatide was most effective (14.34 [5.98–34.35]), followed by Semaglutide_oral (6.86 [2.63–17.90]) and Semaglutide_SC (6.12 [2.97–12.59]) in T2DM. In non‐T2DM, Semaglutide_SC (10.72 [3.29–34.90]) and tirzepatide (4.70 [1.02–21.73]) were effective when compared to placebo. Mixed treatment effects (direct head to head and indirect comparisons) showed that tirzepatide reduced weight more than Semaglutide_oral (MD –6.75% [−8.34 to −5.17]) and Semaglutide_SC (−4.94% [−6.35 to −3.52]) in T2DM and was the only effective agent in non‐T2DM (−16.48% [−21.70 to −11.27]) when compared to placebo. Higher doses enhanced weight loss; nausea/vomiting were more common with tirzepatide (RR 3.64 [2.40–5.52]).
Conclusions
Tirzepatide and Semaglutide_SC are most effective for clinically meaningful weight loss. Optimal dosing and adherence remain essential in practice. Trail Registration: PROSPERO (CRD42024539634).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
- Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Mahasarakham University, Maha Sarakham, Thailand.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
- College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
- Pharmacy Practice Division, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
- UPCOR: UBU Pharmacy Clinical Outcome Research Group, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
ORCID-Profile: Jirawan Vienghirun, Ratree Sawangjit, Nathorn Chaiyakunapruk, Kamlesh Khunti, Shaun Wen Huey Lee
Förderung
- Mahasarakham University
Zitieren
APA
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026). GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70698
Vancouver
Vienghirun J, Sawangjit R, Suttiruksa S, Chaiyakunapruk N, Jinathongthai P, Khunti K, et al. GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70698
BibTeX
@article{Vienghirun2026,
author = {Vienghirun, Jirawan and Sawangjit, Ratree and Suttiruksa, Saithip and Chaiyakunapruk, Nathorn and Jinathongthai, Peerawat and Khunti, Kamlesh and Lee, Shaun Wen Huey},
title = {GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70698}
}
EUVIMED